Metabolic MRI in brain cancer and epilepsy

Metabolic MRI in brain cancer and epilepsy - MINT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53308

Enrollment

Registered

2023-01-27

Start date

2023-09-12

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioma

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: All subjects: - Aged >18 years - Ability to give informed consent - Ability to follow test instructions - Sufficient understanding of the Dutch or English language Glioblastoma Patients in part 2a - Patients who are newly diagnosed with a (suspected) glioblastoma IDH wild type and with a relevant lesion (>1 cm3; prior to surgery) on conventional MRI - Patients who will start treatment according to the Stupp regimen (for part 2a only) Epilepsy Patients in part 1 - Patients diagnosed with epilepsy with a relevant lesion detected by FDG PET Epilepsy Patients in part 2b - Patients diagnosed with epilepsy with or without a lesion on conventional MRI

Exclusion criteria

Exclusion criteria: - The presence of claustrophobia; - MRI-specific exclusion criteria, such as metal implants. - Refusal or inability to provide informed consent - Pregnant or lactating The presence of diabetes mellitus type 1 and 2; The presence of a medical condition which influences brain metabolism

Design outcomes

Primary

Measure	Time frame
Part 1: Quantified rates of brain glucose metabolism; a scan is successfull if an SNR>5 for 2H-Glx is reached Part 2a: Quantified levels of phospholipid metabolites and glucose metabolism in the tumor compared to those levels in healthy brain tissue from the same subject Part 2b: Quantified levels of glucose metabolism in the epileptogenic cortex (determined by either a structural lesion, PET or neurophysiology) compared to healthy brain tissue from the same subject	—

Measure

Time frame

Part 1: Quantified rates of brain glucose metabolism; a scan is successfull if an SNR>5 for 2H-Glx is reached Part 2a: Quantified levels of phospholipid metabolites and glucose metabolism in the tumor compared to those levels in healthy brain tissue from the same subject Part 2b: Quantified levels of glucose metabolism in the epileptogenic cortex (determined by either a structural lesion, PET or neurophysiology) compared to healthy brain tissue from the same subject

—

Secondary

Measure	Time frame
Part 1: Optimal dose of [6,6-2H2]-glucose Optimal timing between administration of [6,6-2H2]-glucose and static DMI Plasma glucose levels Deuterium enrichment of plasma water, lactate and glucose Part 2a: Change in glucose metabolism and phospholipid levels in response to treatment pH levels of the tissue, assed by 31P MRSI redox status of the tissue, assed by 31P MRSI Change in tumor volume, measured on conventional imaging according to RECIST criteria Part 2b: Glucose metabolism compared to FDG-PET metabolism Glucose metabolism in areas with invasive neurophysiological abnormalities	—

Measure

Time frame

Part 1: Optimal dose of [6,6*-2H2]-glucose Optimal timing between administration of [6,6*-2H2]-glucose and static DMI Plasma glucose levels Deuterium enrichment of plasma water, lactate and glucose Part 2a: Change in glucose metabolism and phospholipid levels in response to treatment pH levels of the tissue, assed by 31P MRSI redox status of the tissue, assed by 31P MRSI Change in tumor volume, measured on conventional imaging according to RECIST criteria Part 2b: Glucose metabolism compared to FDG-PET metabolism Glucose metabolism in areas with invasive neurophysiological abnormalities

—

Countries

Netherlands

Contacts

Public ContactE.C. Wiegers

Universitair Medisch Centrum Utrecht

e.c.wiegers@umcutrecht.nl08887553197

Outcome results